当前位置: X-MOL 学术Annu. Rev. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
New-Generation High-Potency and Designer Antibodies: Role in HIV-1 Treatment
Annual Review of Medicine ( IF 15.1 ) Pub Date : 2018-01-29 00:00:00 , DOI: 10.1146/annurev-med-061016-041032
Lucio Gama 1, 2 , Richard A. Koup 1
Affiliation  

Broadly neutralizing antibodies (bNAbs) have been evaluated as promising agents in the fight against infectious diseases. HIV-1-specific bNAbs, in particular, have been tested in both preventive and therapeutic modalities. Multiple bNAbs have been isolated, characterized, and assessed in vitro and in vivo, but no single antibody appears to possess the breadth and potency that may be needed if it is to be used in the treatment of HIV-1 infection. With the technological advances of the past decades, novel and more effective bNAbs have been identified or engineered for higher neutralizing potency, greater breadth, and increased serum half-life. In this review, we discuss the development of a new generation of anti-HIV-1 bNAbs and their potential to be used clinically for treatment and prevention of HIV-1 infection.

中文翻译:


新一代高效药和名牌抗体:在HIV-1治疗中的作用

广泛中和抗体(bNAbs)已被认为是抗击传染病的有前途的药物。尤其是HIV-1特异性bNAb已通过预防和治疗方式进行了测试。已经在体外和体内分离,表征和评估了多种bNAb,但是似乎没有一种抗体具有用于治疗HIV-1感染所需的广度和效力。随着过去几十年的技术进步,已经发现或设计出了新颖且更有效的bNAb,以实现更高的中和效力,更大的广度和更长的血清半衰期。在这篇综述中,我们讨论了新一代抗HIV-1 bNAb的开发及其在临床上用于治疗和预防HIV-1感染的潜力。

更新日期:2018-01-29
down
wechat
bug